Pharmaceutical Giants Mallinckrodt and Endo Explore $7 Billion Merger

Mallinckrodt Pharmaceuticals and Endo Inc. are in talks to merge in a deal valued at approximately $7 billion14.

The potential merger would give each company roughly 50% ownership of the combined entity14.

Both companies have recently emerged from bankruptcy proceedings related to lawsuits over their roles in the U.S. opioid crisis4.

The merged company is expected to be listed on the New York Stock Exchange14.

A deal could be finalized as early as this week, according to sources familiar with the matter1.

The merger would allow the companies to reduce costs and leverage their combined scale for product sales and growth opportunities1.

Both Mallinckrodt and Endo were active in acquiring other businesses during the peak period of large specialty pharmaceutical deals1.

The potential merger reflects ongoing consolidation in the pharmaceutical industry, particularly among companies that have faced legal challenges related to the opioid epidemic4.

Sources:

1. https://www.investing.com/news/stock-market-news/mallinckrodt-and-endo-explore-potential-7-billion-merger--bloomberg-93CH-3924706

4. https://www.marketscreener.com/quote/stock/ENDO-INC-171869506/news/Drugmakers-Mallinckrodt-Endo-in-talks-to-merge-Bloomberg-News-reports-49316260/